Project Grant R01AI198430
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $752K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Baylor College of Medicine $189,159 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating associations between Mycobacterium tuberculosis lineage diversity and host immune response, inflammatory patterns, post-TB lung disease, and treatment response in pulmonary tuberculosis patients in Eswatini. The award is a Project Grant (K23AI193258), structured to...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $427,623 to The Washington University on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research dissecting how HIV-induced immunometabolic perturbation impairs tuberculosis control in people living with HIV despite effective antiretroviral therapy and viral suppression. The research...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $305,908 on December 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of sigma-factor-dependent transcriptional control in Mycobacterium tuberculosis. The research employs experimental and computational approaches to understand the role of an intrinsically disordered region (IDR) in the sigma-A factor, which directs RNA polymerase to genes across...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $798,107 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a tissue-based understanding of tuberculosis-associated lung fibrosis and post-TB lung disease pathology. The project creates a baseline understanding of molecules and cells driving fibrogenesis during TB infection, with the goal of identifying adjunctive therapies to modulate tissue...
- The National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation $795,622 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mycobacterium tuberculosis impact on HIV reservoir clearance. The research examines how tuberculosis disease affects HIV-1 latent reservoirs in people living with HIV. The study will recruit 200 people with HIV, half with active tuberculosis disease, and follow them for up to 18 months....
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded $824,278 to Texas Biomedical Research Institute on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R01AI201766. The award funds comparative investigation of bacterial antigen presentation mechanisms in Mycobacterium tuberculosis and Francisella tularensis infections to...
- The National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation $872,596 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on HIV-1 antibody responses in people living with HIV who have tuberculosis and other opportunistic coinfections. The research examines how tuberculosis changes both the HIV-1 immune response and the characteristics of circulating viruses in coinfected individuals. The project...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital $135,532 on April 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate lipid transport mechanisms in Mycobacterium tuberculosis. The research reveals how MTB controls lipid localization and transport across cellular membranes and the periplasm, focusing on the MCE4 lipid transport system and its role in maintaining native mycobacterial lipids beyond...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Santa Cruz $259,415 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to determine the functional role of long non-coding RNAs (lncRNAs) in tuberculosis infection within macrophages. The research investigates post-transcriptional regulatory mechanisms that control innate immune response to Mycobacterium tuberculosis. The work follows preliminary screening of...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $150,104 on January 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to explore leaderless mRNA translation in mycobacteria as a potential drug target for tuberculosis treatment. The research comprises three aims investigating how mycobacterial ribosomes translate leaderless mRNAs—transcripts lacking the 5' untranslated region and...